Literature DB >> 23681553

Status epilepticus: an update.

Panayiotis N Varelas1, Marianna V Spanaki, Marek A Mirski.   

Abstract

Status epilepticus (SE) still results in significant mortality and morbidity. Whereas mortality depends mainly on the age of the patient as well as the cause, morbidity is often due to the myriad of complications that occur during prolonged admission to an intensive care environment. Although SE is a clinical diagnosis in most cases (convulsant), its treatment requires support by continuous electroencephalographic recording to ensure cessation of potential nonconvulsive elements of SE. Treatment has recently changed to incorporate four stages and must be initiated at the earliest possible time.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681553     DOI: 10.1007/s11910-013-0357-0

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  87 in total

1.  Convulsive Status Epilepticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.

Authors:  Christa B Swisher; Meghana Doreswamy; Krista J Gingrich; James J Vredenburgh; Brad J Kolls
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

3.  Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring.

Authors:  P M Vespa; M R Nuwer; V Nenov; E Ronne-Engstrom; D A Hovda; M Bergsneider; D F Kelly; N A Martin; D P Becker
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

4.  Continuous assessment of electrical epileptic activity in acute stroke.

Authors:  E Carrera; P Michel; P-A Despland; M Maeder-Ingvar; C Ruffieux; D Debatisse; J Ghika; G Devuyst; J Bogousslavsky
Journal:  Neurology       Date:  2006-07-11       Impact factor: 9.910

5.  Successful outcome of episodes of status epilepticus after vagus nerve stimulation: a multicenter study.

Authors:  A Sierra-Marcos; I Maestro; X Rodríguez-Osorio; J Miró; A Donaire; J Aparicio; J Rumiá; M Forcadas; I Garamendi; J Pardo; J López; Á Prieto; G Plans; M Falip; M Carreño
Journal:  Eur J Neurol       Date:  2012-03-26       Impact factor: 6.089

Review 6.  Assessing the outcomes in patients with nonconvulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity.

Authors:  P W Kaplan
Journal:  J Clin Neurophysiol       Date:  1999-07       Impact factor: 2.177

7.  Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.

Authors:  John McIntyre; Sue Robertson; Elizabeth Norris; Richard Appleton; William P Whitehouse; Barbara Phillips; Tim Martland; Kathleen Berry; Jacqueline Collier; Stephanie Smith; Imti Choonara
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

8.  Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus.

Authors:  K B Krishnamurthy; F W Drislane
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

9.  Status epilepticus in children, adults, and the elderly.

Authors:  R J DeLorenzo; A R Towne; J M Pellock; D Ko
Journal:  Epilepsia       Date:  1992       Impact factor: 5.864

10.  Refractory status epilepticus: a prospective observational study.

Authors:  Jan Novy; Giancarlo Logroscino; Andrea O Rossetti
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

View more
  2 in total

Review 1.  Super-Refractory Status Epilepticus.

Authors:  Mauricio Ruiz Cuero; Panayiotis N Varelas
Journal:  Curr Neurol Neurosci Rep       Date:  2015-11       Impact factor: 5.081

2.  Monitoring the Burden of Seizures and Highly Epileptiform Patterns in Critical Care with a Novel Machine Learning Method.

Authors:  Baharan Kamousi; Suganya Karunakaran; Kapil Gururangan; Matthew Markert; Barbara Decker; Pouya Khankhanian; Laura Mainardi; James Quinn; Raymond Woo; Josef Parvizi
Journal:  Neurocrit Care       Date:  2020-10-06       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.